Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field
Roche has bought Inflazome for €380 million ($451 million) upfront to gain control of treatments for inflammatory diseases.…
Novartis Inks Up-to-$5.7B Second Collaboration with Monte Rosa
Nearly a year after licensing Monte Rosa Therapeutics’ Phase II-bound autoimmune disease candidate MRT-6160, Novartis has agreed to…
Swiss centenarians show youthful blood protein profiles in aging study
In Switzerland, 0.02% of the population lives beyond the age of 100. Could there be biological characteristics associated…